REG - Nuformix PLC - Board Changes

NuformixAnnouncement

28/07/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220728:nRSb0002Ua&default-theme=true

RNS Number : 0002U  Nuformix PLC  28 July 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET
ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK
MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

28 July 2022

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

Board Changes

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce the appointment of Dr Daniel ("Dan") Gooding as an Executive Director
of the Company with effect from 1 August 2022.

 

Dr Gooding was a co-founder of Nuformix and the Company's CEO until June 2020.
 He instigated the Company's NXP002 programme as an inhaled therapy for the
treatment of Idiopathic Pulmonary Fibrosis (IPF) and has been acting as a
consultant to the Company since March 2022.  He has over 22 years' experience
in commercialisation and business development within the pharmaceutical
industry, having received his PhD in chemistry from Leeds University.  Dan
began his career in commercial roles with pharmaceutical excipients companies
including FMC and Dow Corning.  At Accelrys Ltd, Dan was responsible for
sales across the UK and Southern Europe, leading business development within
the emerging nanotechnology, drug delivery and formulation sectors, achieving
licensing deals with Johnson & Johnson and AstraZeneca.  Since June 2020,
Dan has remained close to the fields of fibrosis, oncology and drug
repurposing.  Dan supported the management team of Qureight Limited in
securing funding and establishing this Cambridge-based start-up, which
develops AI-based image processing methods in measuring disease progression
and drug response for patients with fibrotic lung diseases including IPF.
 Dan has also cofounded TRx Biosciences, a company developing new oral
therapies using a novel targeted delivery technology to improve treatment of
various cancers and CNS diseases.

 

In addition, Dr Julian Gilbert, currently a Non-executive Director of the
Company has been appointed to the role of Non-executive Chairman.  Following
these changes the board of the Company will comprise Dr Julian Gilbert,
Non-executive Chairman, Dr Dan Gooding, Executive Director, and Maddy Kennedy,
Non-executive Director.

 

Other than as set out in this announcement there are no further disclosures
required in respect of Dr Daniel John Gooding under paragraph 9.6.13 of the
Listing Rules.

 

Commenting, Dr Julian Gilbert, Non-executive Chairman of Nuformix, said: "I am
pleased that Dan has agreed to join the board as an Executive Director.  He
brings significant history with Nuformix and experience to the table which
will help facilitate the progression of our assets, and in particular our
NXP002 programme.  I believe that we now have a board and management
structure appropriate for the Company's needs in order to optimise value from
its assets while maintaining tight control of costs.  I look forward to
providing further updates in due course as we progress."

 

Enquiries:

 

 Nuformix plc
 Dr Julian Gilbert, Non-executive Chairman         Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABDLLLLDLBBBX